What is AVR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.66B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AVR?

P/E (TTM) is n/a and 52-week range is $3.30 to $11.05 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AVR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AVR?

The company profile lists revenue (TTM) near $2M, net income (TTM) near $-10.34B, EPS (TTM) near $-1.93 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Anteris Technologies Global Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Eagan, Minnesota, US, 97.3M shares outstanding, ISIN US03675P1021 when available from company profile and filing metadata.

Anteris Technologies Global Corp

$AVR

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$6.77

+2.11%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. The company is headquartered in Eagan, Minnesota and currently employs 174 full-time employees. The company went IPO on 2024-12-13. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The firm's ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.

Employees

174

Website

anteristech.com/

IPO

2024-12-13

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)